EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia–Telangiectasia

Alessia Romano, Rocco Buccheri, Chiara Zagni, Antonio Rescifina

Chemical Biology & Drug Design · 2026-07 · 108 (1)

DOI: 10.1111/cbdd.70354 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-07-01. Written by Alessia Romano and 3 co-authors. Institution: Department of Drug and Health Sciences, University of Catania, Catania, Italy. Major MEDLINE topics: Syk Kinase, Drug Repositioning, Neuroprotective Agents, Protein Kinase Inhibitors. 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: Italian Ministry of Health, Piano di Sviluppo e Coesione del Ministero della Salute 2014-2020, Ministero della Salute.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Ataxia–Telangiectasia (AT) is a rare neurodegenerative disorder characterized by progressive neuronal loss and chronic neuroinflammation. Emerging evidence indicates that aberrant overexpression of the adaptor protein TYROBP promotes sustained recruitment and activation of spleen tyrosine kinase (SYK), contributing to pathogenic inflammatory signaling in AT. In this study, we applied a drug repositioning strategy to identify clinically approved compounds that inhibit SYK activity. An integrated in silico workflow was employed, combining convolutional neural network (CNN)–based molecular docking with network medicine analysis using the SAveRUNNER platform to screen a library of 2342 FDA‐approved drugs. The top‐ranked candidates were further evaluated using long‐timescale molecular dynamics simulations and post‐simulation redocking to assess their binding stability and conformational persistence within the SYK catalytic pocket under explicit solvent conditions. This multilevel computational analysis identified vemurafenib and palbociclib as the most promising SYK inhibitors, both exhibiting sustained binding affinity and stable intermolecular interactions following protein relaxation. These findings support the feasibility of repurposing FDA‐approved drugs to modulate SYK‐driven neuroinflammatory pathways and provide a mechanistic framework for developing novel neuroprotective interventions for AT.

Subjects

MeSH terms (MEDLINE)

Syk KinaseDrug RepositioningNeuroprotective AgentsProtein Kinase InhibitorsAtaxia TelangiectasiaHumansMolecular Docking SimulationMolecular Dynamics SimulationCatalytic Domain

Author keywords

Ataxia–TelangiectasiaSYK kinasedrug repositioningmolecular dockingmolecular dynamicsnetwork medicinestructure‐based drug design

Substances

Syk KinaseNeuroprotective AgentsProtein Kinase InhibitorsSYK protein, human

Authors and institutions

  • Department of Drug and Health Sciences, University of Catania, Catania, Italy.

Funding

  • Italian Ministry of Health, Piano di Sviluppo e Coesione del Ministero della Salute 2014-2020
  • Ministero della Salute

Cite

APA

Romano, A., Buccheri, R., Zagni, C., & Rescifina, A. (2026). In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia–Telangiectasia. Chemical Biology & Drug Design, 108(1). https://doi.org/10.1111/cbdd.70354

Vancouver

Romano A, Buccheri R, Zagni C, Rescifina A. In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia–Telangiectasia. Chemical Biology & Drug Design. 2026;108(1). doi:10.1111/cbdd.70354

BibTeX
@article{Romano2026,
  author = {Romano, Alessia and Buccheri, Rocco and Zagni, Chiara and Rescifina, Antonio},
  title = {In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia–Telangiectasia},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {108},
  number = {1},
  doi = {10.1111/cbdd.70354}
}
Start for free →